Key facts
- This page summarizes Richard A. Heyman's Form 4 filing for RayzeBio, Inc..
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 27 Feb 2024, 16:59.
Richard A. Heyman - 26 Feb 2024 Form 4 Insider Report for RayzeBio, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 26 Feb 2024
- Net transaction value
- -$22,965,375
- SEC form
- 4
- Accepted by SEC
- 27 Feb 2024, 16:59:10 UTC
- Prior SEC filing
- 20 Feb 2024
- Next SEC filing
- 21 Mar 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ Jeff Woodley, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Richard A. Heyman filed Form 4 for RayzeBio, Inc. on 27 Feb 2024.
Change
- Previous filing in this sequence was filed on 20 Feb 2024.
- Current net transaction value: -$22,965,375.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
RYZB
transaction
Common Stock
Disposed to Issuer
- Transaction value
- $22,965,375
- Shares
- -367,446
- Change %
- -100%
- Price
- $62.50
- Shares after
- 0
- Date
- 26 Feb 2024
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Section 16 status
Richard A. Heyman is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.
Explanation of responses 1 footnote
Footnote F1
Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated December 25, 2023, by and among RayzeBio, Inc. (the "Issuer"), Bristol-Myers Squibb Company ("BMS") and, by way of a joinder dated December 26, 2023, Rudolph Merger Sub Inc., a wholly owned subsidiary of BMS ("Purchaser"), on February 22, 2024, Purchaser completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of BMS (the "Merger"). Pursuant to the terms of the Merger Agreement, the Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive the $62.50 per Share in cash, without interest, subject to any applicable withholding of taxes (the "Cash Amount"). At the effective time of the Merger, each issued and outstanding Share was cancelled in exchange for the Cash Amount.